Look for:

Our offer for

ALEXION PHARMACEUTICAL INC


ISIN:
US0153511094
WKN:
015351109

2020/11/27 19:00:00
Price
123.83 USD
Difference 0.73% (0.90)

General attributes

ISINUS0153511094
SymbolALXN
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)22,753 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)122.01 USD (100)
Ask (Ask size)127.50 USD (400)
Open122.57 USD
High124.00 USD
Low122.06 USD
Close (prev. day)122.93 USD
VWAP123.481334 USD
Volume (pcs)440,843
Trading volume54,447,458.26
Number of trades8,000
Last size62,811

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Annual report: ALEXION PHARMACEUTICAL INCPDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2020/11/27 19:00:00
Price
123.83 USD
Difference 0.73% (0.90)

General attributes

ISINUS0153511094
SymbolALXN
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)22,753 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)122.01 USD (100)
Ask (Ask size)127.50 USD (400)
Open122.57 USD
High124.00 USD
Low122.06 USD
Close (prev. day)122.93 USD
VWAP123.481334 USD
Volume (pcs)440,843
Trading volume54,447,458.26
Number of trades8,000
Last size62,811

Performance and Risk

6M1Y3Y
Perf (%)+21.11%+7.55%+13.18%
Perf (abs.)+21.43+8.63+14.32
Beta0.920.720.92
Volatility36.8240.7638.96
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)122.42 USD (1,109,022)
Ø price 30 days | Ø volume 30 days (pcs.)122.34 USD (1,443,084)
Ø price 100 days | Ø volume 100 days (pcs.)113.26 USD (1,867,393)
Ø price 250 days | Ø volume 250 days (pcs.)107.50 USD (2,141,883)
YTD High | date128.57 USD (2020/10/09)
YTD Low | date72.67 USD (2020/03/16)
52 Weeks High | date128.57 USD (2020/10/09)
52 Weeks Low | date72.67 USD (2020/03/16)

All listings for ALEXION PHARMACEUTICAL INC

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Xetra2020/11/2717:35103.48 EUR0.002
Vienna Stock Exchange2020/11/2717:32103.66 EUR0.013
Tradegate2020/11/2722:26103.60 EUR0.016
Stuttgart2020/11/2711:53103.40 EUR0.048
Nasdaq2020/11/2719:00123.83 USD54.458,000
Munich2020/11/2708:08103.48 EUR0.002
London Stock Exchange2020/11/1716:13126.742 USD0.031
Frankfurt2020/11/2715:52102.58 EUR0.003
Duesseldorf2020/11/2719:30103.36 EUR0.0021
Berlin2020/11/2708:21103.02 EUR0.002

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=91355&ID_TYPE_IMAGE_LOGO=2

Contact Details

ALEXION PHARMACEUTICALS INC.
Chris Stevo
Seaport Boulevard 121 02210 Boston Massachusetts
Telefon: +1-475-230-2596
Fax: +1-203-271-8198
E-mail: IR@Alexion.com

PDF Downloads

Annual report: ALEXION PHARMACEUTICAL INCPDF Download

Company Profile

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. As the global leader in complement inhibition, Alexion is strengthening and broadening its portfolio of complement inhibitors, including evaluating potential indications for eculizumab in additional severe and ultra-rare disorders. Alexion's metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, Strensiq® (asfotase alfa) to treat patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) to treat patients with lysosomal acid lipase deficiency (LAL-D). In addition, Alexion is advancing the most robust rare disease pipeline in the biotech industry with highly innovative product candidates in multiple therapeutic areas.

Members of Management Board

David R. BrennanChairman of Board of Directors
Paul A. FriedmanMember of Board of Directors
Ludwig N. HantsonMember of Board of Directors
Judith ReinsdorfMember of Board of Directors
John T. MollenMember of Board of Directors
Francois NaderMember of Board of Directors
Deborah DunsireMember of Board of Directors
Christopher J. CoughlinMember of Board of Directors
Felix J. BakerMember of Board of Directors
Andreas RummeltMember of Board of Directors
Ludwig N. HantsonChairman of Managing Board
Uzair QadeerMember of Executive Committee
Tanisha CarinoMember of Executive Committee
Rana StrellisMember of Executive Committee
Morgan SanfordMember of Executive Committee
John OrloffMember of Executive Committee
Indrani FranchiniMember of Executive Committee
Ellen ChiniaraMember of Executive Committee
Brian GoffMember of Executive Committee
Aradhana SarinMember of Executive Committee






Accept

We use cookies and web analysis software to give you the best possible experience on our website. By continuing to browse this website, you consent for these tools to be used. For more details and how to opt out of these, please read our Data protection policy.

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).

The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.

Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended). For this reason, the distribution or redistribution of the information, materials and products into United States or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited. The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.

The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.

By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.